Deargen-Samsung Medical Center signed a joint research agreement using ‘AI for The Development of Alzheimer Treatment’

On the July 30th, 2021, Deargen, a biotech company that develops artificial intelligence (AI) drugs, announced that there was a research cooperation agreement with Professor Seo Sang-won, head of the Center for Dementia Convergence Research Center at Samsung Seoul Hospital, to discover new Alzheimer’s treatments using AI technology.